MoonLake Immunotherapeutics (MLTX) CEO awarded 520,342 stock options

Rhea-AI Filing Summary

MoonLake Immunotherapeutics’ Chief Executive Officer, Jorge Santos da Silva, received a grant of stock options covering 520,342 derivative securities on January 7, 2026. These options give him the right to buy up to 520,342 of the company’s Class A ordinary shares at an exercise price of $11.29 per share. The award vests in four equal annual installments on January 7 of 2027, 2028, 2029 and 2030, as long as he continues serving the company through each vesting date. Following this grant, he beneficially owns 520,342 stock options directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Santos da Silva Jorge

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG V8 6300

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.29	01/07/2026		A		520,342		(1)	01/07/2036	Class A ordinary shares, par value $0.0001 per share	520,342	$0	520,342	D

Explanation of Responses:

1. This option represents a right to purchase a total of 520,342 of the Issuer's Class A ordinary shares, vesting in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

	/s/ Matthias Bodenstedt, Attorney-in-fact for Jorge Santos da Silva	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MoonLake Immunotherapeutics (MLTX) report?

MoonLake Immunotherapeutics reported that its Chief Executive Officer, Jorge Santos da Silva, was granted 520,342 stock options on January 7, 2026, giving him the right to purchase the company’s Class A ordinary shares.

What is the exercise price of the CEO’s new stock options at MoonLake (MLTX)?

The stock option grant to the CEO has a conversion or exercise price of $11.29 per share for the underlying Class A ordinary shares.

How do the 520,342 MoonLake (MLTX) stock options vest for the CEO?

The 520,342 stock options vest in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to the CEO’s continued service to MoonLake Immunotherapeutics through each vesting date.

How many MoonLake (MLTX) derivative securities does the CEO hold after this Form 4 transaction?

After this reported transaction, the CEO beneficially owns 520,342 derivative securities (stock options) directly.

Was the MoonLake (MLTX) CEO’s option transaction reported as direct or indirect ownership?

The Form 4 reports the CEO’s ownership of these 520,342 stock options as direct (D) ownership, with no separate nature of indirect beneficial ownership listed.

What type of security was granted to the MoonLake (MLTX) CEO in this Form 4?

The security granted is a Stock Option (Right to Buy) that is exercisable into MoonLake Immunotherapeutics’ Class A ordinary shares, par value $0.0001 per share.